Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Ocular Drug Delivery Devices Market size was valued at USD 15.69 billion in 2024 and is set to exceed USD 43.71 billion by 2037, expanding at over 8.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of ocular drug delivery devices is estimated at USD 17.82 billion.
The growth of the market can be attributed to the growing prevalence of ocular diseases, such as cataracts, uncorrected myopia, and presbyopia, combined with better treatment and care through drug-delivery devices. The drug delivery devices work better than traditionally used eye drops and ointments, as they are not wiped away through tears. This ensures constant and longer-lasting drug delivery, resulting in quicker and more effective relief. Such factors are estimated to boost market growth.
Along with this, the growing prevalence of eye-related diseases is expected to propel the market growth. According to the data from the World Health Organization (WHO), 2.2 billion people have some kind of vision impairment, out of which 1 billion people have moderate or severe distance vision impairment or blindness. Among these, an unaddressed refractive error caused 88.4 million impairments, cataracts caused 94 million, glaucoma was responsible for 7.7 million, and diabetic retinopathy caused 3.9 million vision impairment or blindness cases globally, as of 2018. Eyes are extremely sensitive organs, owing to which, there is a higher awareness regarding the health of the eyes, amongst people, especially in developed countries. As a result, the demand for the treatment of ocular diseases is also elevated, which is projected to positively influence market growth.
Ocular Drug Delivery Devices Sector: Growth Drivers and Challenges
Growth Drivers
-
Increasing Prevalence of Ocular Diseases Across the World – Vision impairment and sight are the most common diseases in children and adults. The occurrence can be congenital or acquired after birth owing to certain circumstances or accidents. The increasing occupational hazards and exposure to metal scrap pieces while welding or cutting can cause vision loss or severe damage to the eye. Also, the growing number of nerve diseases affect the neurons of the brain and affect the functioning of the eye. All these reasons are estimated to propel the market growth in the coming years.
Worldwide over 2 billion population is suffering from near or far vision loss as of 2022 estimations.
-
Growing Number of Eye Disorders Owing to Occupation – As per the U.S. reports, approximately 18,000 eye injuries take place every year at workplaces.
-
Increasing Geriatric Population Across the World with Rising Eye Disorders – According to the estimations of 2021, about 1% of adults in the U.S. 50 years and above age are having visual acuity impairment or blindness, and is estimated to rise by over 19% in people aged 85 and above.
-
Rising Government Expenditure for Healthcare – The national healthcare expenditure of the U.S. in 2021 increased by 3% accounting for over 18% of the gross domestic product
Challenges
-
Poor bioavailability of the dosage forms
The ocular dosage forms have poor bioavailability owing to the loss of precorneal flow which involves lacrimation, dilution with tears, conjunctival absorption, draining of solution, transient residence, and nonproductive absorption. The liquid eye medications flow down the eye as soon as the eye is closed and the solid medications stay in one place taking so much time to distribute by melting. Hence these limitations are expected to hamper the market growth.
-
High Competition from Generic Products
-
Discomfort, such as Irritation, and Excessive Lachrymation
Ocular Drug Delivery Devices Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.2% |
|
Base Year Market Size (2024) |
USD 15.69 billion |
|
Forecast Year Market Size (2037) |
USD 43.71 billion |
|
Regional Scope |
|
Ocular Drug Delivery Devices Segmentation
Disease Type (Glaucoma, Diabetic Macular Edema, Diabetic Retinopathy, Macular Degeneration, Cataract, Refractive Issues)
The market is segmented and analyzed for demand and supply by disease type into glaucoma, diabetic macular edema, diabetic retinopathy, macular degeneration, cataract, refractive issues, and others out of which, the cataract segment is anticipated to hold a substantial share in the global market over the forecast period on account of high cases of cataract globally. Moreover, various government initiatives to spread awareness about cataracts, are anticipated to boost the segment growth. The increasing geriatric population increases the risk of cataracts are estimated to propel the market growth. The market growth is attributed to poor medical facilities and increasing incidence of other disease conditions such as hypertension, diabetes, eye trauma, and eczema. As per the estimations, globally over 15 million population with age 50 and above are suffering from blindness as of 2020.
Type (Topical, Iontophoresis, Ocular Insert, Intraocular Implants, In-situ Gel)
The global ocular drug delivery devices market is also segmented and analyzed for demand and supply by type into topical, iontophoresis, ocular insert, intraocular implants, in-situ gel, and others. Amongst these segments, the intraocular implants segment is expected to garner a significant share. The increasing mortality rate owing to the infections of bacteria and viruses and vision impairment are estimated to boost the market growth. The Increasing screentime of people with work-from-home jobs, IT jobs, software jobs, and growing animation jobs is also driving the growth of the market as per the market analysis. The disposable income of people leads to increased use of smartphones, television (TV), and gaming stations which increase the risk of eye disorders and occurrence of blindness among people. As of 2022 reports, more than 50% of Americans spend time watching TV for one to four hours a day, and over 20% watch TV more than four hours per day.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Drug Form |
|
|
By Diseases Type |
|
|
By End User |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Ocular Drug Delivery Devices Industry - Regional Synopsis
North American Market Forecast
North America industry is poised to dominate majority revenue share by 2037. The growth of the market can be attributed majorly to growing cases of ocular diseases in underdeveloped countries. As per a WHO report, the instances of distance vision impairment in low-income regions are estimated to be four times higher than in high-income regions, and near vision impairment is estimated to be 80% more in western, eastern, and central sub-Saharan Africa. The rising pharmaceutical sector and increasing research and development to improve the drug delivery system of diseases are estimated to hike the market growth. The growing number of collaborations and increasing market players in the region also propel the market growth.
The market in the North American region is anticipated to gain the largest market share throughout the forecast period owing to the growing cases of cataracts and diabetes-related visual conditions in the region. An estimated 20.5 million (17.2%) Americans aged above 40 years have a cataract in one or both eyes, according to statistics by the Centers for Disease Control and Prevention (CDC).
Companies Dominating the Ocular Drug Delivery Devices Landscape
- Bausch Health Companies Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Taiwan Liposome Company, Ltd.
- Ocular Therapeutix, Inc.
- Kiora Pharmaceuticals, Inc.
- Graybug Vision Inc.
- Apellis Pharmaceuticals, Inc.
- Implanet Company
- Aerie Pharmaceuticals Inc.
- EyePoint Pharmaceuticals, Inc.
- Protalix BioTherapeutics
Recent Developments
-
EyePoint Pharmaceuticals, Inc. announced the interim data from its ongoing Phase 1 DAVIO trial of EYP-1901 for the potential treatment of wet AMD.
-
EyeGate Pharmaceuticals, Inc. announced the first successful dosage of its drug PP-001 in the phase II proof-of-concept (“POC”) study of ocular surface inflammation. PP-001 is an inhibitor of dihydroorotate dehydrogenase
- Report ID: 4029
- Published Date: Dec 20, 2024
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Ocular Drug Delivery Devices Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
